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IMPLEMENTATION OF ELECTRONIC PATIENT REPORTED OUTCOME 
MEASUREMENT IN A SAFETY-NET RADIATION ONCOLOGY CLINIC: 
FEASIBILITY, INITIAL QUALITY OF LIFE OUTCOMES, AND SOCIAL 
NEEDS ASSESSMENT 
 
REBECCA NIKA TSAI 
ABSTRACT 
Background 
Patient reported outcomes (PROs) are important cancer outcomes that can be 
measured electronically but are understudied in the safety-net hospital setting. Routine 
electronic screening to address social determinants of health (SDH) has been established 
in primary care clinics and the emergency department of New England’s largest safety-
net hospital. The burden of SDH in safety-net oncology patients is less well-studied. 
This study aimed to determine the feasibility and challenges of routine 
administration of ePROMs in a safety-net Radiation Oncology clinic, describe treatment 
toxicities and quality of life (QOL) experienced by this vulnerable population during 
radiotherapy, and evaluate SDH and the need for SDH screening in the oncology clinic. 
 
Methods 
Patients with lung or head and neck cancer scheduled for radiation oncology 
consultation from 3/2019–1/2020 were deemed eligible for electronic questionnaire 
participation based on primary language spoken and absence of metastases. At 
consultation, patients were administered a set of baseline ePROMs (EQ-5D-3L, FACT, 
	
	 vi 
PRO-CTCAE) and a social needs screener (THRIVE) using a widely-used cloud-based, 
patient-centered outcomes platform. Associations between patient demographics and 
questionnaire completion were retrospectively evaluated. The set of ePROMs were 
collected at the end of treatment to characterize treatment-related toxicities and changes 
in self-reported QOL.  
 
Results 
In total, 99 eligible head and neck cancer (51.5%) and lung cancer (48.5%) 
patients were identified. Median age was 65. The majority of patients were male (71.7%), 
and English-speaking (82.8%). Whites, Blacks, and Asians/Others comprised 42.4%, 
38.4%, and 6.1% of patients, respectively. Fifteen patients were Hispanic (15.2%). 
Patients were most likely to have private health insurance (39.4%), followed by joint 
Medicare-Medicaid (25.3%), Medicaid (17.2%), and Medicare (16.2%). Two patients 
were insured by Corrections (2.0%).  
Eight patients (8.1%) no-showed or cancelled, while 91 patients were seen in 
consultation. Forty-four patients (48.4%) completed the initial questionnaires. For the 
remaining 47 patients (51.6%), the most common reason for lack of ePROM completion 
was clinic understaffing and/or clinical decision based on the absence of indication for 
radiotherapy (n=27, 57.4%). Ten patients refused to complete questionnaires (21.3%), 
with reasons cited including length of questionnaires and low energy. Ten patients were 
physically unable to attempt questionnaires (21.3%), for reasons including disabilities 
and low-literacy. Age, language, race, ethnicity, insurance, marital status, gender, and 




For patients who completed the general (QOL) questionnaire EQ-5D-3L, there 
was no significant difference in general QOL domains nor self-reported overall health 
score at baseline vs. end of treatment. For head and neck cancer patients, FACT-H&N 
Total scores, measuring disease-specific QOL, were significantly worse at end of 
treatment vs. baseline (P=0.006). For lung cancer patients, FACT-L Total scores at the 
end of radiation treatment were not significantly worse at end of treatment vs. baseline 
(P=0.953). For head and neck cancer patients who completed PRO-CTCAE, there was a 
significant increase in the number with moderate to very severe taste issues (P=0.008) 
and decrease in appetite (P=0.025) by end of treatment. For lung cancer patients, there 
was a trend towards an increase in the number reporting moderate to very severe nausea 
(P=0.083). 
Eighty-one of 99 patients (81.8%) were screened for at least one SDH domain 
using the THRIVE screener at the study hospital. Nineteen patients (19.1%) had all 8 
THRIVE social determinants of health statuses documented. Only housing status was 
documented for 61 patients (61.6%). There was a trend for married individuals (P=0.068) 
and females (P=0.074) to be associated with the completion of at least one THRIVE 
domain. Age, race, language, and insurance status were not associated with THRIVE 
screening (P>0.05). Transportation to appointments (21.1%), food insecurity (20%), and 
affording medications (10.5%) were the most prevalent concerns among these oncology 
patients, with 100% of patients who reported insecurities with medication and 





Routine ePROs collection in a busy safety-net oncology setting is feasible, but 
challenging and labor-intensive. Implementation was met with both patient and staff 
challenges and revealed the need for dedicated project management, staff training, and 
opportunities to increase patient accessibility. Preliminary PROs analyses revealed 
several significant detriments in quality of life and increased symptoms for this patient 
population during treatment, but additional data collection is required.  
 
Safety-net oncology patients report significant social needs. Routine SDH 
screening and resource referral should be considered in these vulnerable patients. Efforts 
in a specialized department such as Radiation Oncology could fill gaps in existing efforts 
in a large safety-net hospital. Safety-net oncology clinics can likely help vulnerable 
cancer patients access available community resources and reduce disparities due to SDH.  
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Quality of cancer care is evaluated by patient outcomes. With improvements in 
the delivery of and access to cancer prevention, screening, treatment, and survivorship 
care, the United States has seen a steady decline in mortality rates due to cancer.1 From 
1991 to 2016, the overall cancer death rate has decreased consistently by a total of 27%.2 
Overall survival and other outcomes such as progression-free survival and recurrence, are 
objective outcomes and have traditionally been used by clinicians to assess the 
effectiveness of cancer care.3 Other patient outcomes, such as quality of life (QOL) and 
adverse events (AE), also inform clinicians of the drawbacks and benefits of treatments.4  
 
Clinician Reported Outcomes 
Cancer patient outcomes have typically been reported by clinicians. In cancer 
clinical trials, clinician reported outcomes (CROs) focus on the reporting of AEs.5 First 
developed in 1983, the National Cancer Institute’s (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) is a standardized library of AEs that is used in clinical 
trials for routine evaluation of treatment toxicity to ultimately inform drug benefit-to-risk 
ratio and lead to Food and Drug Administration (FDA) approval.6,7 AEs are defined as 
any unfavorable and unintended sign, symptom, or disease temporally associated with the 
use of medical treatment or procedure and used specifically for medical documentation 
and scientific analyses.5,8 The CTCAE assesses the severity of AEs on a graded scale but 
does not consider the duration of AEs or the impact of treatment on quality of life. 
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Additionally, CROs have been shown to have poor concordance with patient self-report 
of the same symptoms.5 Evidence suggests that clinicians underestimate treatment 
toxicity onset and severity. The patient’s viewpoints on the effectiveness of treatment, 
health, and well-being are not captured in CROs and objective measures.9 The sole use of 
traditional methods of outcomes measurement may overlook equally valuable patient 
reported data. Inclusion of the patient perspective in outcomes measurement may more 
accurately and holistically capture health outcomes to inform future practices. 
 
Patient Reported Outcomes 
Recognizing the limitations of objective outcomes and CROs, and to better 
capture the patient’s perspective of illness, treatment, and quality of life, patient reported 
outcome measures (PROMs) were developed to evaluate patient reported outcomes 
(PROs). A PRO is defined as any report directly from patients, without interpretation by 
others, about how they function or feel in relation to a health condition and its therapy.10 
These outcomes are measured using validated PROMs, which typically measure 
symptom status, functional status, or quality of life.9 PROMs are developed on the basis 
that patient self-report provides a unique perspective on therapy, as some effects of 
disease and its therapy are best characterized by the patient. This ultimately can provide 
more sensitive and specific measurements of the effects of therapies, increasing 
efficiency and accuracy of attempts to describe drug benefit-to-risk ratio in clinical 
trials.10 Examples of validated PROMs are EuroQol Group’s EQ-5D, which assesses 
general health status, and FACIT’s Functional Assessment of Cancer Therapy (FACT), 
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which assesses disease-specific quality of life.11,12 Both PROMs were developed in the 
early 1990s.  
The benefits of PRO collection are manifold. PROs can assess the severity of 
symptoms, monitor and track patient outcomes over time, inform treatment decisions, and 
allow for clearer patient-provider discussion of care.13 PROs have been shown to assist 
clinicians and patients in selecting the best treatment option by providing a clearer and 
more holistic picture of the costs and benefits of treatment.14 Patient reported assessments 
capture outcomes that can be missed or underreported by clinicians, and be more reliable 
than clinician reported assessments.15–17 PROMs can also more effectively capture patient 
quality of life, a complex multi-dimensional concept that includes physical functioning, 
psychological and social well-being, personal beliefs, level of independence, and 
relationship to the environment.18 For example, knowledge of patient reported symptoms 
could help providers identify and discuss the impact of treatment and account for possible 
AEs related to chemotherapy.19 PRO data can broaden clinician understanding of the 
patient experience with information that direct observable outcomes cannot provide, as 
certain domains, such as pain and fatigue, are more difficult to characterize from the 
clinician perspective.14 PROs can also inform future clinical trial methods and cancer 
care, with demonstrated prognostic and predictive significance, including prediction of 
survival outcomes.14,20,21 PROs have been associated with improved safety and treatment 
compliance,15 leading to improvement in survival rates and reduced visits to the hospital 
and emergency room.22 Use of PROs would enhance resource utilization and lower 
overall healthcare costs.20 
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Though PROMs have been available for decades, there has only been a shift in 
cancer care in recent years to value patient-centered care and the use of PROMs. A 
systemic shift was initiated in 2009 by the FDA’s guidelines on the use of PROMs in 
clinical trials.23 As a companion to the CTCAE, the NCI put forth the PRO-CTCAE in 
2015, a validated PROM.6,24 This PROM includes a library of 78 symptomatic toxicities 
drawn from the CTCAE and measures their frequency, severity, and/or interference in 
QOL. However, use of the PRO-CTCAE, or evaluation of any patient reported outcomes 
with other PROMs, is not required by the NCI in cancer clinical trials, who states that the 
standard for grading and reporting all AEs remains clinician grading using the CTCAE.6  
Nonetheless, there is substantial and growing interest in measuring patient-
reported outcomes in clinical trials and incorporating PROs in routine cancer care.25 
Although the FDA, NCI, and oncology-specific societies, such as the American Society 
of Clinical Oncology (ASCO) have been enthusiastic for this type of patient-centered 
approach,26,27 most oncology trials and FDA approved medication still do not include 
PROs, with reasons cited such as cost, logistics, burden on patients and clinicians.28 Even 
fewer are the number of cancer centers that systematically collect PROs as part of routine 
cancer care. In a health care system that values efficiency and effectiveness, additional 
energy and resources allocated to PRO collection are of understandable concern. Thus, 
innovative approaches to enhance efficiency and effectiveness of patient-provider 
communication will ensure the delivery of quality care and reduce avoidable healthcare 
costs. Studies have shown how PROMs in various platforms allow patients to provide 
information about their health and providers to access this data in real-time to prioritize 
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topics of discussion during office visits. 29 Feasibility and reasonable cost of collecting 
patient-reported symptomatic AEs in various cancer clinical trials using the web, tablet 
computers, paper, and telephone systems have been well documented.17,30,31 Additionally, 
evaluation of the feasibility of weekly completion of PROMs in a lung cancer 
chemoradiation trial showed that over 85% of patients were willing and able to self-
report PRO-CTCAE items on tablet computers in clinic waiting rooms at expected time 
points during active treatment.17 These tablets were brought to patients by site staff at 
treatment visits. Other studies show that clinical staff responsiveness to PROs collected, 
which led to discrete clinical interventions and modifications in care.22 The resources 
required for symptom monitoring with PROs not only improves patient overall well-
being, satisfaction of care, and survival rates, but will reduce health care expenditures 
such as emergency room visits and hospitalization.22,32 One other noteworthy hindrance 
to regular use of PROs in oncology settings may be the FDA’s concerns that patients are 
not able to provide unbiased reports of their own symptoms.23,28 However, review of 5 
randomized, double-blind negative trials revealed no significant differences in PROs 
between patient groups, and there was no compelling evidence of bias associated with 
knowledge of treatment.16 
Though there is significant evidence for the value, importance, and feasibility of 
routine PROs collection, only some clinical trials and a select number of cancer centers 
have implemented routine PROs collection.5,7,14–17,19–22,29–38 Even fewer are the number of 
safety-net oncology settings that have allocated resources to consider systematic 
collection of patient self-reported information. While the American Cancer Society’s 
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cancer statistics of 2019 describe an overall decrease in cancer mortality rates, more in-
depth analyses reveal growth in socioeconomic inequalities, with the most notable gaps 
for preventable cancers. Between 2012 and 2016, mortality rates for male lung cancer 
were 40% higher and cervical cancer 2-fold higher in the poorest U.S. counties compared 
to the most affluent counties.2 Further, some states were home to both the most affluent 
and poorest counties, suggesting the need for more equitable implementation of effective 
cancer prevention, intervention, and survival care and application of existing cancer care 
knowledge on disadvantaged populations. With growing evidence for the benefits of 
routine PRO collection, recent studies describe its feasibility in clinical trials and select 
oncology practices.14,15,17,19,29–31,33–35,37,38 However, patient data from these studies are 
generated from a predominantly White and educated patient population. Lacking is data 
on the implementation of routine PRO collection and characterization of its feasibility 
and challenges in the safety-net hospital oncology setting, where patients are often of 
minority racial groups, may not speak English, and are of lower education and medical 
literacy levels. PROs have not been well studied in the safety-net hospital setting where a 
medically and socially vulnerable group of patients are at risk of disparities in cancer 
outcomes.  
In addition to the benefits of PROs collection as described in other settings, PROs 
can address unique challenges for vulnerable patient populations. Evaluation of PROs 
before, during, and after treatment can capture important information on vulnerable 
cancer patients’ symptom burden and the impact of treatment on short-term and long-
term QOL.22 PROs provide an assessment of the patient’s experience of illness.13 In the 
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face of language and cultural barriers, PROs can allow for clearer communication of 
patient symptoms and concerns to clinicians, and shed light on unmet needs or 
expectations of treatment.36 This enhances patient engagement and shared decision 
making, and provide data for patient advocacy with policy implications. Routine 
collection of patient-reported assessments has the potential to lead to the delivery of more 
culturally sensitive and population-specific care, and ultimately foster empowerment of 
vulnerable patient populations. As disparities and unmet needs are identified, 
interventions can be inspired, and cancer outcomes improved. Routine PROs collection 
can be enhanced through the use of electronic patient reported outcome measures 
(ePROMs), which has enabled more efficient, cost-effective, and accurate patient data 
collection.19,38 Feasibility of routine ePROM or PROM administration in a safety-net 
oncology setting has not been previously studied and established. 
 
Social Determinants of Health Screening at Boston Medical Center 
Boston Medical Center (BMC) is the largest safety-net hospital and busiest 
trauma and emergency services center in the New England area, where 57% of patients 
are from under-served populations and 32% of patients do not speak English as a primary 
language.39 BMC provides care for predominantly low income, minority, immigrant, and 
urban populations. In 2015, 1416 new cancers were diagnosed at BMC, and 35% of these 
patients were black. Half of all cancer patients receive radiotherapy as part of their 
treatment. In order to better understand the impact of cancer and its treatment on this 
medically underserved patient population, the Department of Radiation Oncology at 
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BMC implemented routine electronic PROM administration via computer tablets at office 
visits.  
There is growing evidence that cancer outcomes are influenced by social 
determinants of health (SDH)2, varying greatly with race, socioeconomic status (SES), 
health insurance coverage, education, geographic area of residence, and structural 
inequalities.1,40,41 Besides ePROMs, the Department of Radiation Oncology also 
electronically implemented the THRIVE screening tool to collect patient self-reported 
social needs status. THRIVE is a social determinants of health screening and electronic 
resource referral system developed at BMC.40 Federal and state policies are beginning to 
provide incentives for health systems to better address unmet social determinants of 
health needs of patients, with the goal of providing high quality of care while reducing 
the cost of health care.42 In view of this goal, THRIVE was developed by an 
interdisciplinary committee of health, policy, and information technology experts and 
designed to help clinicians understand the social needs that impact their patients’ health, 
improve patient care by communicating these needs to care teams, and ultimately provide 
patients with information on resources available in the community.40 The implementation 
and feasibility of THRIVE in 6 ambulatory primary care clinics of General Internal 
Medicine at BMC were characterized in 2017, and social needs screening through 
THRIVE is now a routine aspect of primary care at BMC. Most recent reports in 2019 of 
over 57,000 patients screened showed that 28% of patients reported having at least one 
social need and 19% of these patients requested resources.42 Housing, food, and problems 
affording medications were the most prevalent health-related social needs of these 
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primary care patients. As cancer control efforts are aimed at the continuum from 
prevention to survivorship and palliative care, they should also be aimed at the continuum 
of influences, including SDH.43 However, the burden of SDH in safety-net oncology 
patients remains understudied. Failure to aim cancer control efforts on SDH will 
perpetuate, and potentially widen, cancer outcome disparities. 
 
Specific Aims 
Given the lack of data on PRO collection in a safety net oncology patient 
population, this study focused on the implementation of electronic questionnaires in the 
Radiation Oncology Department at BMC and aimed to:  
1. Establish the feasibility of routine administration of electronic questionnaires to 
collect PROs and SDH needs in a diverse and understudied oncology patient 
population.  
2. Describe treatment toxicities, adverse events, and quality of life using validated 
ePROMs before and after the course of radiation treatment. 
3. Describe SDH needs of a vulnerable cancer patient population and evaluate the 








Electronic health record (EHR) software Epic Systems and ARIA Varian Medical 
Systems were queried weekly to identify patients with either head and neck cancer or 
lung cancer arriving in the Radiation Oncology clinic at Boston Medical Center for 
radiotherapy consultations. Patient reported assessments were collected from eligible 
patients as part of routine clinical care. Institutional review board approval was obtained 
before conducting a retrospective analysis of patient, disease, and treatment factors, and 
questionnaire responses.  
 
Study Patients 
Patients with lung or head and neck cancer scheduled for radiation oncology 
consultation from 3/2019 – 2/2020 were deemed eligible for questionnaire participation 
based on primary language spoken (English, Spanish, French, Portuguese) and absence of 
metastases. These languages were selected based on the demographics of the patient 
population seen at Boston Medical Center, and availability of validated translations for 
the selected PROMs.   
 
Demographic Variables 
Using EHR (Epic and ARIA), patient demographic variables were collected 
including age at clinic presentation, gender, race (White/Black/Other), ethnicity 
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(Hispanic/Non-Hispanic), insurance status (private, Medicare, Medicaid, Medicare-
Medicaid, corrections), marital status, and primary language spoken. The primary site 
was categorized as head and neck cancer and lung cancer as determined by International 
Classification of Diseases 10th revision (ICD-10) code assigned to patients in the EHR.  
 
ePROM Interface 
An institution-specific, HIPAA secure electronic PROM interface was designed in 
collaboration with the patient-centered outcomes company VisionTree Software, Inc. The 
company provides a widely used, cloud-based platform designed for patient-centric data 
exchange and outcomes tracking.44 The questionnaires were configured to allow for 
patients to answer on electronic tablets after checking into the Department of Radiation 
Oncology and before their appointments with the clinician. The interface allowed 
ambulatory service representatives to assign disease-specific ePROMs according to a 
patient’s cancer disease and set a radiation therapy start date that then prompted 
automated questionnaire activation at pre-specified time intervals.  
 
Questionnaire Administration 
Specific ePROMs were selected for administration at baseline, weekly during 
radiotherapy, at end of treatment, and in follow-up at 3, 6, 9, 12, 18, 24, 36, 48, and 60 
months after treatment. At each time point, patients were administered the set of 
ePROMs in their preferred language on a tablet, using the VisionTree platform. Patients 
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were directed to complete these questionnaires in a clinic room or one of three waiting 
areas in the department and return the electronic tablet to a staff member.  
The PROMs selected to capture multi-dimensional aspects of patients’ health and 
quality of life were the EuroQOL EQ-5D, Functional Assessment of Cancer Therapy – 
General (FACT-G), the disease site-specific FACT module (i.e., FACT-H&N for head 
and neck cancer and FACT-L for lung cancer), and items from the Patient-Reported 
Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-
CTCAE™). Validated Spanish, French, and Portuguese translations of the ePROMs were 
provided based on the patient’s language of choice. Permission was obtained from 
EuroQOL and FACT to use these PROMs. 
Starting in July 2019, patients were also administered THRIVE, the social 
determinants of health screening tool at baseline to assess their social needs.  
 
EuroQoL EQ-5D-3L (EQ-5D-3L) 
The EQ-5D-3L is a widely used and validated, non-disease specific instrument to 
assess health-related quality of life45 and was selected as one of the three PROMs 
administered to patients at baseline, end-of-treatment, and at follow-up visits in order to 
capture general, non-cancer-specific QOL domains. The three-level version of EQ-5D 
(EQ-5D-3L) was developed by the EuroQoL Group in the late 1980s, consisting of two 
components: the EQ-5D descriptive system, and the EQ visual analogue scale (EQ VAS; 
see Appendix 1). The descriptive system evaluates five dimensions: mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression.12 Each dimension has the 
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following three levels: no problems, some problems, and extreme problems. Patients 
were asked to indicate their health state by marking the box next to the statement which 
they deemed most appropriate for each of the five dimensions. The EQ VAS captured the 
patient’s self-rated health on a vertical visual scale ranging from 0-100, designed as a 
quantitative measure of health outcome which reflects the patient’s own judgment. The 
questionnaire was designed to be cognitively undemanding and completable in a few 
minutes.12 EuroQOL gave approval for electronic conversion of their questionnaire onto 
the VisionTree platform, and reviewed and approved the final ePROM interface. 
Summary health state scores were obtained from the descriptive system and visual 
analogue scale as directed by EuroQoL.  
 
 
Functional Assessment of Cancer Therapy (FACT) 
Developed by Functional Assessment of Chronic Illness Therapy (FACIT) 
Measurement System, FACT-General (FACT-G) was validated in the early 1990s and 
has since been used in many studies worldwide to measure health-related quality of life 
for patients undergoing cancer therapy.11 The group has since developed and validated 
more than 90 questionnaires, including FACT-Head and Neck (FACT-H&N)46 and 
FACT-Lung (FACT-L)47 for head and neck cancer and lung cancer patients, respectively. 
FACT-H&N (Appendix 2A) and FACT-L (Appendix 2B) are the combination of FACT-
G and a disease-specific subscale.  
The FACT questionnaires are a self-report instrument, used to measure quality of 
life, and is widely used in cancer clinical trials. It is a brief, yet sensitive general cancer 
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quality of life measure for patients undergoing cancer treatment.11 Additionally, FACT-L 
was shown to be a precise indicator of patient reported quality of life for lung cancer 
patients who completed the questionnaire in a clinical trial setting.47 FACT-H&N was 
also validated for head and neck cancer patients.46 Ultimately, quality of life for cancer 
patients is multi-dimensional. Capturing general and disease-specific measurements 
allow general health status and disease-specific concerns to be addressed through the 
assessment of functional and quality of life outcomes.46 
 When comparing FACT-H&N and FACT-L scores at end of treatment to 
baseline, higher scores in domains (Physical, Social, Emotional, Functional Well-Being, 
and Additional disease-specific concerns) are indicative of improved well-being. Physical 
Well-Being (PWB) asks patients to report on items such as lack of energy, meeting the 
needs of family members, forced time in bed. Social/Family Well-Being (SWB) asks 
patients to report on items such as feelings of closeness to family and friends. Emotional 
Well-Being (EWB) asks patients to report on items such as sadness, satisfaction with 
disease coping, worries about dying. Functional Well-Being (FWB) asks patients to 
report on items such as ability to work, enjoyment of life, and sense of fulfillment. The 
Head and Neck Cancer Subscale (HNCS) evaluated additional concerns specific to head 
and neck cancer and asked patients questions such as their ability to eat preferred foods, 
dry mouth, difficulty breathing, quality of voice, and perception of physical appearance 
(Appendix 2A). The Lung Cancer Subscale (LCS) evaluated additional concerns specific 
to lung cancer and asked patients questions such as weight loss, clear thinking, cough, 
chest tightness, quality of breathing, and smoking regret (Appendix 2B).  
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Patient-Reported Outcomes Version of the Common Terminology Criteria for 
Adverse Events (PRO-CTCAE) 
The PRO-CTCAE is a library of validated patient-reported outcome items 
corresponding to items in the NCI’s Common Terminology Criteria for Adverse Events 
(CTCAE), which is used by clinicians to collect and report adverse events (AEs) in 
cancer clinical trials.6,24  
Using a similar ordinal severity scale to the CTCAE, the PRO-CTCAE library 
was designed in response to the evidence that the collection of AE information directly 
from patients improves precision and patient-centeredness in obtaining symptomatic AEs. 
Usage of PRO-CTCAE thus allows for integration of the patient perspective into AE 
reporting.24 
Of the 790 AEs in the CTCAE, 78 AE questions were amenable to patient self-
report.24 Of the 78 PRO-CTCAEs, 23 and 16 AEs were chosen by physicians for the head 
and neck cancer patients and the lung cancer patients, respectively (Appendix 3A and 
3B), for self-assessment in the Radiation Oncology clinic. Physicians selected the PRO-
CTCAEs that were on consensus the most likely to be clinically significant and cause 
QOL impairment while being mindful of the number of items to minimize survey fatigue. 
 
THRIVE 
The THRIVE questionnaire is a social needs screening tool and referral system.40 
THRIVE (Appendix 4) screens for eight SDH domains, captures patient responses as 
ICD-10 diagnosis codes in EHR, and provides patients with resource referral guides to 
	
	 16 
address unmet social needs for when they have indicated desire for help. The eight SDH 
screened domains are housing, food, affording medications, transportation to medical 
appointments, paying utilities, caregiving, education, and employment. The THRIVE 
screening tool was added to the VisionTree platform to obtain patient-reported data on 
social determinants of health affecting the oncology patient population.  
 
Questionnaire Interpretation and Storage 
Results of the completed electronic questionnaires were immediately available 
through HIPAA compliant, secure internet access on the electronic tablet or computers 
for review by the nurse, physician assistant, or physician seeing the patient. Clinicians 
were able to address responses to individual items as well as aggregate domain scores 
based on validated PROM scoring instructions, coded by VisionTree and tested by 
physicians prior to ePROM implementation.  
Data collected through questionnaires were stored in a secure, password-protected 
electronic database by VisionTree, which was extracted to a secure department computer 
for data analysis.  
 
Data Analysis 
Feasibility of ePROM Implementation 
Feasibility was defined as the partial or full completion of the four baseline 
electronic questionnaires given to eligible patients. The magnitude of disparities in 
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patient-reported data by factors such as race, ethnicity, age, gender, primary language, 
marital status, and insurance was evaluated.  
 
Patient Reported Outcomes Before and After Radiotherapy 
Three PROMs, EQ-5D, FACT, and PRO-CTCAE, were used to assess baseline 
patient reported outcomes, as well as treatment-related toxicity and changes in self-
reported quality of life after radiation treatment. Analysis was based on established 
scoring methods for each validated PROM. End of treatment scores were compared to 
baseline scores. Weekly PRO-CTCAE responses during the radiation therapy course 
were assessed by physicians in routine clinical management but not included in this 
study. Similarly, follow-up PROM data from the few patients who completed treatment 
early in the study period were not included in this initial analysis.   
 
Statistical Analysis 
Frequencies (column percent) were computed to describe patient characteristics. 
A chi-square test was used to examine differences in patient characteristics by completion 
and THRIVE status. For patient age, results were presented as median (interquartile 
range, IQR), and non-parametric Wilcoxon-Mann Whitney test was used to assess for 
differences in distribution by completion and THRIVE status. For analysis of race and 
insurance status, tests were repeated after excluding patients with missing data and 
patients treated at corrections facilities, respectively. 
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          For PROMs (EQ-5D, FACT- Head and Neck, FACT- Lung, FACT-Combined, 
PRO-CTCAE-Head and Neck and PRO-CTCAE-Lung), the distribution of scores was 
presented as median (IQR) while frequencies with column percent were computed for the 
response to individual survey questions. The distribution was presented for all patients at 
baseline and patients with complete information at baseline and end of the treatment. The 
McNemar test was employed to examine differences in answers to survey questionnaires 
between baseline and end of the treatment time points. For all the survey questionnaires, 
the answers were categorized into binary outcomes; e.g., for PRO-CTCAE items 
assessing symptom severity, responses were classified as no problem / mild vs. moderate, 
severe, and very severe.  
        Statistical computations were performed on SAS 9.3 system (SAS Institute, Cary, 







Patient and Disease Characteristics 
A total of 106 patients were screened between 3/2019 and 2/2020. Seven patients 
were ineligible to participate in the study due to exclusion criteria; four were ineligible 
because their primary language was unavailable and three were ineligible due to distant 
metastases. A total of 99 eligible head and neck cancer (n=51; 51.5%) and lung cancer 
(n=48; 48.5%) patients were identified and included in the study analysis. Median age 
was 65 (interquartile range 57-72). The majority of patients were male (71.7%), and 
English-speaking (82.8%). Whites, Blacks, and Asians/Others comprised 42.4%, 38.4%, 
and 6.1% of patients, respectively. Fifteen patients were Hispanic (15.2%). Patients were 
most likely to have private health insurance (n=39; 39.4%), followed by joint Medicare-
Medicaid (including senior and community health plans for the elderly) (n=25; 25.3%), 
Medicaid (n=17; 17.2%), and Medicare (n=16; 16.2%). Of note, two patients were 













Table 1. Descriptive data for 99 eligible patients  
 All patients 
N= 99 
 median (IQR) 
Age (years) 65 (57-72) 
 n (column percent) 
Site  
  Head and neck 51 (51.5) 
  Lung 48 (48.5) 
Gender  
  Male 71 (71.7) 
  Female 28 (28.3) 
Race  
  White 42 (42.4) 
  Black 38 (38.4) 
  Asian/Other race 6 (6.1) 
  Not available 13 (13.1) 
Hispanic ethnicity  
  Non-Hispanic 84 (84.9) 
  Hispanic 15 (15.2) 
Primary language spoken  
  English 82 (82.8) 
  Non-English 17 (17.2) 
Marital status  
  Married 25 (25.3) 
  Unmarried1 74 (74.8) 
Insurance status  
  Private 39 (39.4) 
  Medicare 16 (16.2) 
  Medicaid 17 (17.2) 
  Joint Medicaid/Medicare2 25 (25.3) 
  Corrections 2 (2.0) 
1Unmarried include single, divorced, widowed, 
separated and other 
2Joint Medicare-Medicaid including senior and 







Feasibility of ePROM Implementation 
Electronic Questionnaire Completion 
Of the 99 patients who were eligible to receive electronic questionnaires, 8 
patients (8.1%) no-showed or cancelled, while 91 patients were seen in consultation 
(Figure 1). Of these 91 patients, 44 patients (48.4%) completed the initial questionnaires 
at baseline. For the remaining 47 patients (51.6%), the most common reason for lack of 
electronic questionnaire completion was clinic understaffing and/or clinical decision 
based on absence of indication for radiotherapy (n=27, 57.4%). Ten patients refused to 
complete questionnaires (21.3%), with reasons cited including length of questionnaires 
and low energy. Ten patients were physically unable to attempt questionnaires (21.3%), 
for reasons including disabilities and low-literacy. Examining patient and disease 
characteristics, age, language, race, ethnicity, insurance, marital status, gender, and 












Figure 1. Patient eligibility and reasons given for ePROM incompletion
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1P value=0.256 when “Not available” excluded from the analysis 




Patient refusal or inability to complete electronic questionnaires were identified as 
patient-specific reasons for lack of questionnaire completion. In an analysis restricted to 
64 patients who completed the survey (n=44) or did not complete the survey due to 
patient refusal/physical inability (n=20), there continued to be no significant association 






 median (IQR)  
Age (years) 61.5 (57-70) 67 (59-72) 0.140 
 n (column percent)  
Site    
  Head and neck 23 (52.3) 22 (46.8) 0.602 
  Lung 21 (47.7) 25 (53.2)  
Gender    
  Male 30 (68.2) 33 (70.2) 0.834 
  Female 14 (31.8) 14 (29.8)  
Race1    
  White 18 (40.9) 21 (44.7) 0.407 
  Black 15 (34.1) 18 (38.3)  
  Other race 5 (11.4) 1 (2.1)  
  Not available 6 (13.6) 7 (14.9)  
Hispanic ethnicity    
  Non-Hispanic 35 (79.6) 41 (87.2) 0.323 
  Hispanic 9 (20.5) 6 (12.8)  
Primary language spoken    
  English 33 (75.0) 41 (87.2) 0.135 
  Non-English 11 (25.0) 6 (12.8)  
Marital status    
  Married 13 (29.6) 10 (21.3) 0.364 
  Unmarried 31 (70.5) 37 (78.7)  
Insurance status2    
  Private 14 (31.8) 21 (44.7) 0.780 
  Medicare 8 (18.2) 8 (17.0)  
  Medicaid 8 (18.2) 7 (14.9)  
  Joint Medicaid/Medicare 13 (29.6) 10 (21.3)  
  Corrections 1 (2.3) 1 (2.1)  
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between age, disease site, gender, language spoken, race, ethnicity, marital status or 
insurance status and ePROM completion (all P>0.05; Table 2b).  
 
Table 2b. Patient and disease characteristics by ePROM completion status 
(completed vs. not completed due to patient refusal or physical inability) 
 Completed 
N= 44 
Not Completed Due 




 median (IQR)  
Age (years) 61.5 (57-70) 68 (59.5-73.5) 0.073 
 n (column percent)  
Site    
  Head and neck 23 (52.3) 10 (50.0) 0.866 
  Lung 21 (47.7) 10 (50.0)  
Gender    
  Male 30 (68.2) 14 (70.0) 0.884 
  Female 14 (31.8) 6 (30.0)  
Race1    
  White 18 (40.9) 8 (40.0) 0.892 
  Black 15 (34.1) 8 (40.0)  
  Other race 5 (11.4) 1 (5.0)  
  Not available 6 (13.6) 3 (15.0)  
Hispanic ethnicity    
  Non-Hispanic 35 (79.6) 17 (85.0) 0.739 
  Hispanic 9 (20.5) 3 (15.0)  
Primary language spoken    
  English 33 (75.0) 16 (80.0) 0.759 
  Non-English 11 (25.0) 4 (20.0)  
Marital status    
  Married 13 (29.6) 2 (10.0) 0.117 
  Unmarried 31 (70.5) 18 (90.0)  
Insurance status2    
  Private 14 (31.8) 7 (35.0) 0.513 
  Medicare 8 (18.2) 1 (5.0)  
  Medicaid 8 (18.2) 6 (30.0)  
  Joint Medicaid/Medicare 13 (29.6) 5 (25.0)  
  Corrections 1 (2.3) 1 (5.0)  
1P value=0.776 when “Not available” excluded from the analysis 





ePROM Completion Rates 
Of the 44 patients who completed electronic questionnaires at baseline, 42 
patients completed EQ-5D-3L, 43 patients completed FACT, and 37 patients completed 
PRO-CTCAE. At the end of treatment (typically 6-7 weeks later), 21 patients (50.0%) 
completed EQ-5D-3L, 20 patients (46.5%) completed FACT, and 20 patients (54.1%) 
completed PRO-CTCAE. End of treatment completion rates for individual disease sites 
are detailed in Figure 2.  
 
Figure 2. ePROM completion by questionnaire and disease-site 
 





Patient Reported Outcomes Before and After Radiotherapy 
General Quality of Life: EQ-5D-3L 
In an analysis of patients who completed EQ-5D-3L at baseline and at end of 
treatment (n=21), there was no significant difference in general QOL domains at baseline 
vs. end of treatment. Thirteen patients (61.9%) reported mobility problems at baseline 
compared to 11 (52.4%) at end of treatment (P=0.157). Eight patients (38.1%) reported 
problems with self-care at baseline compared to 6 (28.6%) at end of treatment (P=0.414). 
Twelve patients (57.1%) reported problems with usually life activities at baseline 
compared to 13 (61.9%) at end of treatment (P=0.655). Twelve patients (57.1%) reported 
pain/discomfort at baseline compared to 14 (66.7%) at end of treatment (P=0.414). Nine 
patients (42.9%) reported anxiety/depression at baseline compared to 12 (57.1%) at end 
of treatment (P=0.180). There was no difference in patient self-reported overall health 
score. The median VAS score at baseline was 70 (IQR=51-82) compared to 70 (IQR=40-
82) at end of treatment (P=0.757). All dimension scores at baseline and at end of 











136 patients had information on the overall score of 42 patients at baseline. Fifteen 
patients had data on the overall score at both baseline and end of treatment. 
  
Table 3. EQ-5D 






 median (IQR) 
VAS score1 70 (50-81) 70 (51-82) 70 (40-82) 0.757 
     
 n (column percent) 
Mobility    0.157 
Some problem/confined to bed vs. no 
problem 
17 (40.5) 13 (61.9) 11 (52.4)  
     
Self-care    0.414 
Some problem/unable to wash or dress 
vs. no problem 
10 (23.8) 8 (38.1) 6 (28.6)  
     
Usual activities (e.g., work, study, 
housework, family or leisure activities) 
   0.655 
Some problem/unable perform my 
usual activities vs. no problem 
18 (42.9) 12 (57.1) 13 (61.9)  
     
Pain/discomfort    0.414 
Moderate/extreme vs. none 26 (61.9) 12 (57.1) 14 (66.7)  
     
Anxiety/depression     0.180 
Moderate/extreme vs. none 17 (40.5) 9 (42.9) 12 (57.1)  
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FACT-Head and Neck 
Head and neck cancer patients who completed FACT at baseline and at end of 
treatment (n=11) reported significantly worsened FACT-G scores at the end of radiation 
[baseline score 71 (IQR=51.2-98) vs. end of treatment 58 (IQR=50-94), P=0.009]. 
Patients reported worsened Functional Well-Being scores at the end of treatment (median 
12, IQR 6-19) compared to at baseline (median 13, IQR 11-21; P=0.028). Patients also 
reported worsened head and neck cancer-specific concerns scores at the end of radiation 
(median 15, IQR 10-23) than at baseline (median 24, IQR 16-33; P=0.008). Looking at 
FACT-H&N Total scores, patients at the end of radiation treatment had worsened 
summary quality of life scores (median 72, IQR 60-116) than at baseline (median 95, 
IQR 69-135; P=0.006]. All dimension scores at baseline and at end of treatment can be 
found in Table 4a.   
 
Table 4a. FACT- Head and Neck 






 median (IQR) 
Physical Well-Being  23 (17-26) 26 (17-28) 14 (13-25) 0.107 
Social/Family Well-Being 19 (15-25) 19 (8.2-28) 17 (12.8-26) 0.634 
Emotional Well-Being  18 (11-21) 19.2 (11-20) 19 (13-20) 0.905 
Functional Well-Being  13 (8-21) 13 (11-21) 12 (6-19) 0.028 
1FACT-General score 
(PWB+SWB+EWB+FWB) 
71 (56-89) 71 (51.2-98) 58 (50-94) 0.009 
Additional Concerns  
(HNCS score) 
24 (15-33) 24 (16-33) 15 (10-23) 0.008 
2FACT-H&N Total score  
(FACT-G+HNCS) 
91 (72-120) 95 (69.2-135) 72 (60-116) 0.006 
1FACT-General score is the sum of Physical, Social/Family, Emotional, and Functional Well-
Being scores 
2FACT-H&N score is the sum of the FACT-General score and the Head and Neck Cancer 




Lung cancer patients who completed FACT at baseline and at end of treatment 
(n=9) did not report significantly worsened FACT-G scores at the end of radiation 
(median 60, IQR 50.5-89.5) compared to at baseline score (median 67, IQR 62-80.2, 
P=0.910). Similarly, FACT-L Total scores at the end of radiation treatment were not 
significantly worse at end of treatment (median 77, IQR 67-104.5) compared to baseline 
(median 83, IQR 79.2-95, P=0.953). All dimension scores at baseline and at end of 
treatment can be found in Table 4b.   
 
Table 4b. FACT- Lung 






 median (IQR) 
Physical Well-Being  23 (17.5-24.5) 21 (16-23) 17 (13-25) 0.888 
Social/Family Well-Being 21.5 (17.7-24.5) 21 (20-23) 19 (15-24.5) 0.301 
Emotional Well-Being 16 (12.5-17.5) 14 (13-16) 15 (15-18) 0.232 
Functional Well-Being 15 (9-18.5) 14 (9-17) 8 (7-20) 0.953 
1FACT-General score 
(PWB+SWB+EWB+FWB) 
68 (62-84.2) 67 (62-80.2) 60 (50.5-89.5) 0.910 
Additional Concerns  
(LCS score) 
15.5 (12.5-18.5) 16 (15-19.0) 17 (13-20) 0.858 
2FACT-L Total score  
(FACT-G+LCS) 
82.5 (78-102.8) 83 (79.2-95) 77 (67-104.5) 0.953 
1FACT-General score is the sum of Physical, Social/Family, Emotional, and Functional Well-
Being scores 











In an analysis of all cancer patients who completed FACT-G at baseline and at 
end of treatment (n=20), patient reported scores showed a trend towards worsened quality 
of life at the end of treatment (median score 58.5, IQR 50.3-91.8) compared to baseline 
(median score 70.5, IQR 58.2-86.9; P=0.064), Table 4c.  
 
Table 4c. FACT-G 






 median (IQR) 
Physical Well-Being 23 (17-25) 23 (16.5-26) 16 (13-25) 0.223 
Social/Family Well-Being 21 (16-25) 21 (15.6-26.4) 18 (14.5-26) 0.257 
Emotional Well-Being 16 (12-20) 16 (12.5-19.6) 16.5 (14-19.5) 0.329 
Functional Well-Being 14 (9-20) 13.5 (10-20.5) 9 (6.5-19.5) 0.121 
FACT-G score 70 (58-87) 70.5 (58.2-86.9) 58.5 (50.3-91.8) 0.064 




PRO-CTCAE Head and Neck 
Of head and neck cancer patients who completed PRO-CTCAE at baseline and at 
end of treatment (n=10), there was a significant increase in the number of patients who 
reported moderate to very severe taste issues and decrease in appetite. One patient (10%) 
reported moderate to very severe issues tasting food or drink at baseline compared to 8 
patients (80%) who reported so at end of treatment (P=0.008). Three patients (30%) 
reported a moderate to very severe decrease in appetite at baseline compared to 8 patients 
(80%) who reported so at end of treatment (P=0.025). There was no significant difference 
in the number of head and neck cancer patients who reported moderate to very severe dry 
mouth, difficulty swallowing, hoarseness, nausea, vomiting, skin burns, pain, or fatigue at 
baseline compared to at end of treatment. All item scores at baseline and at end of 













13 patients were “not applicable,” leaving 15 patients at baseline and 8 patients 
for baseline vs. end of treatment analysis.  
Note: P-value was not calculated for some analyses as the baseline group did not 
have any patient with moderate, severe or very severe disease 
  
Table 5a. PRO-CTCAE-Head and Neck 






 n (column percent) 
In the last seven days, what was the 
severity of 
 
Dry mouth     0.180 
Moderate, severe or very severe vs. no 
problem or mild 
7 (38.9) 3 (30.0) 6 (60.0)  
Difficulty swallowing     0.564 
Moderate, severe or very severe vs. no 
problem or mild 
8 (44.4) 4 (40.0) 5 (50.0)  
Hoarse voice    0.157 
Moderate, severe or very severe vs. no 
problem or mild 
6 (33.3) 4 (40.0) 6 (60.0)  
Problems with tasting food or drink    0.008 
Moderate, severe or very severe vs. no 
problem or mild 
3 (16.7) 1 (10.0) 8 (80.0)  
Decreased appetite      0.025 
Moderate, severe or very severe vs. no 
problem or mild 
5 (27.8) 3 (30.0) 8 (80.0)  
Nausea    0.317 
Moderate, severe or very severe vs. no 
problem or mild 
2 (11.1) 2 (20.0) 3 (30.0)  
Vomiting    - 
Moderate, severe or very severe vs. no 
problem or mild 
0 (0.0) 0 (0.0) 2 (20.0)  
Skin burns from radiation1    - 
Moderate, severe or very severe vs. no 
problem or mild 
0 (0.0) 0 (0.0) 5 (62.3)  
Pain    0.317 
Moderate, severe or very severe vs. no 
problem or mild 
10 (55.6) 4 (40.0) 5 (50.0)  
Fatigue, tiredness or lack of energy    1.0 
Moderate, severe or very severe vs. no 
problem or mild 




Of lung cancer patients who completed PRO-CTCAE at baseline and at end of 
treatment (n=9), there was a trend towards a significant increase in the number of patients 
who reported moderate to very severe nausea. Two patients (22.2%) reported moderate to 
very severe nausea at baseline compared to 5 patients (55.6%) who reported so at end of 
treatment (P=0.083). There was no significant difference in the number of lung cancer 
patients who reported moderate to very severe difficulty swallowing, decrease in appetite, 
vomiting, shortness of breath, cough, skin burns, pain, or fatigue at baseline compared to 
















1Vomiting, shortness of breath, cough, skin burns from radiation, pain, and 
fatigue were missing from 2, 1, 1, 4, 1, and 2 patients, respectively.  
26 patients were available for baseline vs. end of treatment analysis.  
Note: P-value was not calculated for some analyses as baseline or end of 















 n (column percent) 
In the last 7 days, what was the severity of  
Difficulty swallowing     0.317 
Moderate, severe or very severe vs. no 
problem or mild 
3 (15.8) 1 (11.1) 3 (33.3)  
Decreased appetite      1.0 
Moderate, severe or very severe vs. no 
problem or mild 
6 (31.6) 1 (11.1) 1 (11.1)  
Nausea    0.083 
Moderate, severe or very severe vs. no 
problem or mild 
3 (15.8) 2 (22.2) 5 (55.6)  
Vomiting    - 
Moderate, severe or very severe vs. no 
problem or mild 
0 (0.0) 0 (0.0) 0 (0.0)  
Shortness of breath    0.564 
Moderate, severe or very severe vs. no 
problem or mild 
6 (33.3) 4 (44.4) 5 (55.6)  
Cough    0.655 
Moderate, severe or very severe vs. no 
problem or mild 
10 (55.7) 4 (44.4) 5 (55.6)  
Skin burns from radiation2    - 
Moderate, severe or very severe vs. no 
problem or mild 
0 (0.0) 0 (0.0) 3 (33.3)  
Pain    0.317 
Moderate, severe or very severe vs. no 
problem or mild 
8 (44.4) 3 (33.3) 5 (55.6)  
Fatigue, tiredness or lack of energy    0.157 
Moderate, severe or very severe vs. no 
problem or mild 
8 (47.1) 3 (33.3) 5 (55.6)  
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Assessment of Social Determinants of Health and Social Needs 
Availability of Patient SDH Status 
Eighty-one of 99 patients (81.8%) were screened for at least one SDH domain 
using the THRIVE screener at Boston Medical Center. Nineteen patients (19.1%) had all 
8 THRIVE social determinants of health statuses documented in EHR (Figure 3). Only 
housing status was documented for 61 patients (61.6%). Only housing and food 
insecurity status were documented for 1 patient (1.0%).  
 





Association of Demographics and THRIVE Screening Completion 
Patient and disease characteristics were analyzed for association with receipt and 
completion of the THRIVE screening tool. There is a trend in association with married 
	
	 36 
individuals (P=0.068) and females (P=0.074) with completion of at least one THRIVE 
domain. Age, race, language, and insurance status were not associated with availability of 
THRIVE data (P>0.05; Table 6).  
 
Table 6. Patient and disease characteristics by THRIVE completion status   
 THRIVE data 
N= 81 
No THRIVE data 
N= 18 
P 
 median (IQR)  
Age (years) 65 (58-71) 65.5 (57-74) 0.443 
 n (column percent)  
Site    
  Head and neck 41 (50.6) 10 (55.6) 0.705 
  Lung 40 (49.4) 8 (44.4)  
Gender    
  Male 55 (67.9) 16 (88.9) 0.074 
  Female 26 (32.1) 2 (11.1)  
Race1    
  White 33 (40.7) 9 (50.0) 0.297 
  Black 34 (42.0) 4 (22.2)  
  Other race 5 (6.2) 1 (5.6)  
  Not available 9 (11.1) 4 (22.2)  
Hispanic ethnicity    
  Non-Hispanic 70 (86.4) 14 (77.8) 0.465 
  Hispanic 11 (13.6) 4 (22.2)  
Primary language spoken    
  English 68 (84.0) 14 (77.8) 0.505 
  Non-English 13 (16.1) 4 (22.2)  
Marital status    
  Married 17 (21.0) 8 (44.4) 0.068 
  Unmarried 64 (79.0) 10 (55.6)  
Insurance status2    
  Private 33 (40.7) 6 (33.3) 0.316 
  Medicare 11 (13.6) 5 (27.8)  
  Medicaid 14 (17.3) 3 (16.7)  
  Joint Medicaid/Medicare 22 (27.2) 3 (16.7)  
  Corrections 1 (1.2) 1 (5.6)  
1P value=0.419 when “Not available” excluded from the analysis 





Social Needs Demonstrated and Resources Requested 
Transportation to medical appointments (21.1%), food insecurity (20%), and 
inability affording medications (10.5%) were the most prevalent concerns among these 
oncology patients (Table 7). Housing insecurity, utilities, caregiving, unemployment, and 
education were identified social concerns for 4-5% of patients. Of the 17 instances in 
which a need was reported, resources were requested on 9 instances (52.9%). All patients 
(100%) who reported insecurities with affording medication, transportation to 













Reported insecurity Requested 
resources 
 n (percent) 
    
Housing/Shelter N= 81 3 (3.7) 0 (0.0) 
    
Food N= 20 4 (20.0) 2 (50.0) 
    
Paying for Medicines N= 19 2 (10.5) 2 (100.0) 
    
Transportation to 
medical appointments 
N= 19 4 (21.1) 4 (100.0) 
    
Paying for Utilities N= 19 1 (5.3) 1 (100.0) 
    
Caregiving N= 19 1 (5.3) 0 (0.0) 
    
Job Searching N= 19 1 (5.3) 0 (0.0) 
    
Education 
 
N= 19 1 (5.3) 0 (0.0) 
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Gaps in SDH Status Screening 
Social needs screening implementation and feasibility in 6 primary care clinics at 
BMC through use of THRIVE has been shown.40 However, patients have subsequently 
reported social needs through THRIVE screening in other settings, such as the emergency 
department and inpatient units. Of the 61 patients who only had housing status on file and 
the 1 patient who had housing and food insecurity status on file, 100% of these patients 
reported on these statuses in settings other than primary care. Of the 19 total patients who 
had complete documentation of all 8 SDH domains of THRIVE, 12 patients (63.2%) 
reported on all 8 domains for the first time through Primary Care settings and 7 patients 
(36.8%) did so through Radiation Oncology. Before Radiation Oncology implementation 
of the THRIVE screening tool, 12 patients (12.1%) had complete THRIVE 
documentation. After implementation of this tool, the Radiation Oncology Department 
successfully screened 7 patients, all of whom had never received the full THRIVE 
screening before, increasing the total number of patients with full THRIVE 
documentation to 19 out of all 99 eligible patients (19.2%).  
In a further analysis of patients registered after introduction of THRIVE screening 
in the Radiation Oncology clinic (n=55) and excluding 6 patients who did not arrive to 
clinic (no-show/cancellation), 49 patients were eligible to complete THRIVE screening. 
Of the 49 patients, 6 patients (12.2%) had all THRIVE data in EHR and 26 patients 
(53.1%) had only housing data on file prior to arrival in clinic. Of the 17 patients (34.7%) 
with no THRIVE data prior to arrival, 7 patients (41.2%) completed the full THRIVE 
screening tool for the first time (Figure 4).  With the addition of the 7 patients who 
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received full THRIVE screening for the first time in Radiation Oncology, there was a 
14.3% increase in the rate of screening to 79.6% (39 patients).  
 
 









This study aimed to establish the feasibility of electronic questionnaire 
implementation and routine ePROs collection in a safety-net oncology clinic, to observe 
cancer self-reported outcomes for these patients through the use of PROMs, to capture 
their SDH status, and to determine the need for continued SDH screening in the 
Radiation Oncology Department at BMC.  The findings contribute evidence to support 
the feasibility of routine ePROs collection in a safety-net oncology clinic. Additionally, 
the findings suggest social needs screening identifies patient concerns, and that efforts in 
a specialized department such as Radiation Oncology could fill gaps in existing efforts at 
BMC. The findings in this study expand upon the current literature available on the 
imperative need to incorporate routine PROs collection in clinical trials and cancer care.  
 
Feasibility of ePROM Implementation 
 We confirm that the patients arriving for cancer care in the Radiation Oncology 
Department are of a diverse and vulnerable, safety-net population. Eligible patients in this 
study were primarily elderly or male. While the majority of patients were English-
speaking, almost 20% of patients primarily spoke a language other than English. Almost 
40% of the eligible were Black and over 15% identified as Hispanic. The percentage of 
Black patients (38.4%) who were eligible to receive electronic questionnaires was 
comparable to the percentage of Black patients (39.9%) screened through the THRIVE 
study in 6 BMC Primary Care Clinics between 2017-2018.40 Over half of patients 
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(58.7%) had non-private health insurance and 2% of patients were insured by 
Corrections. 
We show that it is feasible for patients in a safety-net hospital setting to complete 
questionnaires on electronic devices, with almost 50% of eligible patients completing 
initial ePROMs at baseline. Of the 44 patients who attempted questionnaires at baseline, 
more patients seemed to have completed the EQ-5D and FACT vs. the PRO-CTCAE. 
This may have been due to the order of ePROM presentation. Compliance in completing 
ePROMs after baseline decreased over time as seen in other PROM and ePROM studies 
involving more homogenous groups of patients.5,17  
While age, language, race, ethnicity, insurance status, marital status, gender and 
disease site were not associated with electronic questionnaire completion, elderly or 
unmarried patients seemed to demonstrate a pattern of association with questionnaire 
incompletion among patients who refused or who were physically unable to complete 
questionnaires compared to patients who completed questionnaires, after removing 
patients who did not complete questionnaires due to staff-related reasons.  
 
Challenges of Implementation 
Implementation of an electronic questionnaire system in a busy safety-net 







Of patients who met eligibility criteria but were physically unable to complete 
ePROMs, vision difficulty, preferred language unavailable, illiteracy, physical/logistical 
difficulties due to incarceration, patient mental status, patient difficulty with the tablet or 
electronic questionnaire user-interface, feelings of weakness or tiredness, difficulties due 
to physical disabilities, and patient inability to complete without assistance were reasons 
recorded for inability to complete ePROMs. These reasons for missing ePROs data 
reflect a more elderly and diverse patient population than in comparable studies in 
clinical trials, with cited reasons for incompletion such as vacation, patient too tired, 
illness, poor internet connectivity, missed clinic visits, and staff error.17 This study found 
that patient assistance was needed in not only accessing electronic questionnaires, but 
also in completion. Reasons why patients refused to complete ePROMs when physically 
able was less well documented and should be more systematically captured in the future.  
Prior studies have noted the importance of considering the frequency at which 
PRO assessment may become burdensome to patients and staff.31,36 In one study 
assessing feasibility of administering the entire PRO-CTCAE item library in a cancer 
clinical trial setting, patients were willing and able to complete the full item library at 
three time points.36 Other studies show high adherence rates on consecutive visits 
regardless of number of symptomatic AEs assessed. 17,22,24,37 In one study which 
described feasibility of PRO assessment in a clinical trial setting with dedicated PRO 
staff, PROs were administered daily.36 While the argument can be made that answering 
electronic questionnaires can be burdensome for an older, more diverse, less educated 
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population with more comorbidities, the findings of this study suggest that obtaining 




Staffing challenges were a major source of missing ePROs data in this study. Of 
patients who did not attempt questionnaires at baseline, 57.4% of patients did not attempt 
due to clinical decision and/or clinic understaffing. Clinical decisions to withhold 
questionnaires were not documented in an organized manner due to a lack in clear 
workflow. Known clinical decisions to withhold questionnaires included change in 
treatment plans and assessment by front desk staff or providers that the patient was not a 
good candidate. Incomplete ePROs data was also due to missed ePROM administration 
due to staffing error or oversight in a busy clinic. On occasion, patients who claimed 
questionnaire completion had not fully completed all questionnaires. This was only 
discovered once computer tablets were already returned to clinic staff and the patient had 
left the clinic.  
Creation of an electronic questionnaire system in a safety-net hospital setting 
revealed the need for dedicated project management, leadership, and staff training, as 
suggested in other studies,36,38 but with a special focus on targeting the unique challenge 
of increasing patient inclusion in a diverse, vulnerable patient population. Similar to past 
ePRO implementation in select clinics,38 this study found the challenges faced in 
implementation in a safety-net oncology setting included integrating the electronic 
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questionnaire administration into the clinic workflow. The workflow implemented in this 
study relied on staff at the front-desk to approach patients with electronic tablets. Eligible 
patients and patients already enrolled in the study were missed when multiple patients 
arrived in clinic at once. Though other staff members (radiation therapists and nurses) 
were also trained to assist, high patient volume, already overwhelmed staff, lack of 
dedicated on-site personnel, clear delegation of responsibilities, and lack of 
communication resulted in missing patients who should have received electronic 
questionnaires. It was also not feasible for staff follow patients for the entire duration that 
they were in clinic, to ensure and confirm full questionnaire completion. As tablet 
administration was a team effort, there lacked documentation of clinical decisions to 
withhold questionnaires from enrolled patients when deemed unfit for study participation, 
resulting in a number of eligible patients who did not complete electronic questionnaires 
and no record of reasons for incompletion.  
Once patients had successfully received a tablet and begun ePROMs, patients 
would sometimes be called from the waiting room to their weekly treatment or 
appointment before having completed their assigned electronic questionnaires. There may 
have been increased reluctance by both patients and staff to prioritize questionnaire completion 
after the visit, if patients were called from waiting rooms before they completed questionnaires. It 
is likely that this safety-net population requires more intensive resources to ensure ePROs 
were completed successfully. When pressured for time, clinic staff prioritized their 
established responsibilities, such as administering treatment, while ensuring questionnaire 
completion was deemed a lower priority. In a study about clinical trial staff members’ 
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experiences with PRO studies, staff felt they lacked guidance and training for PRO 
studies.36 Possible ways to improve confirmation of questionnaire completion include 
having dedicated staff, increasing “buy-in” from other staff by teaching and enforcing the 
importance of measuring ePROs for patient care, and ensuring staff is not overwhelmed 
with clinic primary responsibilities. 
The challenges of administration in a safety-net setting are similar to that found in 
other studies involving cancer clinical trial coordinators,48 which have shown that PRO 
administration procedures are often unclear regarding participants who were unable to 
complete questionnaires, handling participants’ family members who attempted to 
complete PROMs, and whether to approach patients or already enrolled patients who 
appeared unwell or distressed.48 Flexibility to participants’ needs while also adhering to 
set protocols is paramount in collecting ePROs. Lack of training and inconsistent 
guidelines could lead to confusion and use of inconsistent methods.  
 
Strengths and Limitations 
This study provides valuable information on the feasibility of routine 
administration of electronic questionnaires to collect patient self-reported outcomes in a 
diverse and understudied oncology patient population.  
These findings and methods should be useful to others who are interested in 
administering electronic questionnaires to patients with varying physical needs, 
backgrounds, languages, and SES. A strength of this study is its detailed information on 
patient demographics, such as preferred language, marital status, insurance status, and 
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race, data that has been lacking in other studies characterizing routine questionnaire 
feasibility and administration in cancer care and clinical trial settings.17,22,24,31,34–38,48 The 
inclusion of patients of various underserved demographics, including incarcerated 
patients, suggests its applicability to diverse US cancer populations.  
There are limitations to this study, which affect the generalizability of the 
findings. The sample size was relatively small. Site-specific differences in workflow, 
staffing, and practice culture influence ePRO use in clinic. Future use of ePROMs in the 
department and elsewhere can take into account the implementation strategies and 
challenges faced detailed in this study to facilitate workflow and management 
improvement and changes in resource allocation, especially as PROs collection scales up 
to include more patients.   
Similar to other studies, substantial numbers of study patients did not have ePRO 
data available at end of treatment, or at 3 months after treatment and onward.  While in 
other studies, patients had died or discontinued treatment,37 many of our patients 
discontinued for personal reasons or reasons that were not captured. Of note, this study is 
an interim analysis and includes patients who have not finished treatment and entered the 
post-treatment follow-up phase yet.  
 
Future Directions 
The creation of an ePRO system and the challenges which arose during 
implementation in a safety-net hospital setting points to future steps in order to broaden 
patient inclusion in a diverse patient population. Future directions and studies will 
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continue to follow a quality improvement approach to systematically improve this ePROs 
collection and utilization initiative.  
Obtaining stakeholder feedback should be prioritized in order to improve ePROM 
experience for all who are involved. Feedback should be systematically obtained from 
patients, providers, and clinic staff.17,40 For patients, survey questions should be aimed at 
better capturing and  understanding reasons for refusal and non-compliance, experience 
with the electronic questionnaire interface, perceived usefulness of surveys, and general 
areas of improvement. Short refusal surveys or interviews can also be conducted at time 
of refusal. This will inform future improvements to ePROM administration and increase 
survey completion rates and patient enrollment. For clinicians and staff, short structured 
surveys at set intervals can be administered to understand how to improve workflow, 
PROs utility, and increase compliance.48 To do this, staff specific surveys can include 
items such as gauging staff baseline knowledge of ePROM procedures,49 perceptions and 
attitudes of ePROM system,36 and challenges faced in ePROM administration. Receiving 
and reviewing feedback will allow the department to improve workflow, increase 
compliance, and optimize patient and staff experience.  
As feedback is solicited, immediate actions can be taken to enhance accessibility 
of ePROMs and reduce missing PROs data. The implementation process revealed 
opportunities to increase accessibility for patients who were physically unable to 
complete ePROMs. Different modes of computer tablet transportation and tablet stands 
can be used for different patients with different needs. For example, a mobile tablet stand 
may be unsuitable for incarcerated patients who arrive in clinic with limited upper-
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extremities mobility, and thus a different mode of ePROM administration can be used 
which allows for self-reporting with ease. Current VisionTree interface can be modified 
in various ways to improve patient experience, especially for those with vision issues or 
difficulty with interface navigation. Questionnaire appearance can be modified to 
increase readability and to prevent questionnaire submission without completion of all 
questions. Future steps should involve working with VisionTree programmers to further 
improve the questionnaire interface. While completion rates were lower at end of treatment 
compared to at start of treatment, as seen in other PROM and ePROM studies involving 
more homogenous groups of patients,5,17 training patients on using devices, streamlining 
questionnaires, using more ergonomic devices, and improving user interface design 
should increase compliance.  
Several languages were frequently requested in the clinic, such as Arabic and 
Vietnamese, but could not be included due to lack of validation for each PROM in that 
language. We could partner with other stakeholders to request that EQ-5D, FACT, and 
PRO-CTCAE develop and validate their questionnaires in other languages. Non-text 
interfaces such as audio-guidance, computer dictation, which is routinely used in the 
department, can be requested to assist those who may be illiterate or have vision 
difficulty, but are eligible for questionnaire completion otherwise.  
The department has taken steps to expand electronic questionnaire administration 
to include gynecological cancers and gastrointestinal cancers. As our analysis 
demonstrated that completion of PROMs proved to be too time-consuming or 
burdensome for some patients, a shorter list of PRO-CTCAE items has been selected for 
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these cancers, and the existing list for lung and head and neck cancers was also 
shortened.  
 Resource investment, guided by feedback into staff ePROM experience, will 
increase staff compliance and reduce missing PROs data. Previous studies have shown 
the necessity of dedicated personnel, project management staff, and training for the 
successful implementation of routine PROs collection into clinic workflow.36,38 
Dedicated project staff may train patients to use the electronic system, administer tablets 
in waiting rooms, ensure completion of questionnaires before treatment or appointment 
with clinician, respond to patient symptom alerts generated by questionnaires, and 
address questions and technical issues.31,50 Presence of assigned staff to monitor 
questionnaire completion and ensure protected time and space of completion will prevent 
the time needed to follow up with patients with incomplete forms and obtain missing 
PROs data. These trained staff members may also review PROs data before the patient is 
seen by the provider and bring up concerning items of certain threshold for the provider 
to discuss with the patient. Dedicated project leadership may create formalized guidelines 
for ePROs operations and oversee compliance. 
Staff training on ePROs operations is of paramount importance in a busy 
oncology clinic to improve coordination of patient care. Clear roles should be assigned 
and role-specific training given on the use and value of ePROMs and PROs to all staff 
involved.48 Clinicians may be trained on areas such as importance and use of PROs (e.g., 
reviewing PRO reports and alerts), interpretation of scores, and discussion of PRO scores 
with patients.50 Training should also involve education on the purpose and value of 
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PROs. It may be beneficial to discuss the relationship between the usage of PROs and 
increased quality of care and improved patient-provider communication. Increased PRO 
compliance, work satisfaction, and participant retention has been shown in clinical trial 
groups as a result of involving trial coordinators and nurses more actively in the research 
process and investing resources in their professional development.36 
It is unclear whether all clinicians involved responded to actionable PRO reports 
in this study. Prior studies in homogenous patient populations have explored the benefits 
of PROs which showed increased rates of patient-physician discussions of symptoms,32 
increased symptom management by clinicians in response to patient reports, 51 and 
improved symptom control when patients reports are shared with clinicians.32,51 
Systematic patient reporting appears to enhance clinician awareness and can augment 
existing mechanisms for symptom management during routine oncology care. 
Conversely, when undetected in the absence of patient self-reporting, symptoms may 
continue to worsen and cause serious complications, lead to hospital visits, limit the 
ability to safely deliver chemotherapy, and diminish outcomes.37 Future discussions 
should examine current provider capacity to respond to ePROs49 and how to include 
ePROs collected in patient-provider discussions.20 This will be an important step towards 
fully integrating PROs as a therapeutic objective in routine care for this underserved and 
diverse patient population.20 
The study found that accessing and reviewing ePROs in an independent electronic 
software may be burdensome for clinicians and impeded workflow in a busy oncology 
clinic, which is similar to what other cancer centers have found.52 Moreover, system ease 
	
	 51 
of use is necessary for sustainability. Currently, the VisionTree-generated ePRO data is 
visible only in a separate system from Epic, the existing EHR system. While integration 
of PRO reports into Epic would significantly streamline PRO review by clinicians, 
preliminary research into this possible solution proved to be costly and would require 
financial and operation decisions beyond a single department’s control. Improving 
VisionTree and Epic software interoperability would increase efficiency, lower staff 
burden, and streamline delivery of higher quality of care. However, integration of ePROs 
system with existing EHR may raise legal concerns such as specifications of patient and 
provider responsibilities of PROs collection and storage.13,53  
Key considerations for implementation of ePROMs should include the resources 
and workflow in place to administer ePROMs and collect ePROs data, stakeholder 
perceived value of PROs data, and capacity of staff to respond to PROs data.49 We show 
the feasibility and challenges of routine ePROs collection in a safety-net oncology 
setting, demonstrating its successful operation in cancer care, and more specifically, for 
the first time within existing PROs literature, for a diverse and underserved cancer 
population.   
 
Patient Reported Outcomes Before and After Radiotherapy 
In preliminary data analyzing patients who completed the EQ-5D-3L at baseline 
and at end of treatment (N=21), there was no difference in overall patient self-reported 
health-related quality of life, as indicated by the VAS score. Of patients who completed 
FACT-H&N at baseline and at end of treatment (N=11),  disease-specific quality of life 
	
	 52 
using FACT-H&N, patients reported significantly worsened Functional Well-Being, 
FACT-General, Head and Neck Cancer Subscale and FACT-H&N scores at the end of 
radiation treatment. Of patients who completed FACT-L at baseline and at end of 
treatment (N=9), patients reported worsened Social/Family Well-Being, Emotional Well-
Being, and FACT-General scores at the end of radiation treatment. However, patients 
reported improved Lung Cancer Subscale scores, which suggests that the decreased 
median FACT-L score was due to decrease in general quality of life rather than lung 
cancer-specific concerns. There was an overall trend towards lower FACT-General 
scores from baseline to end of treatment (P=0.064), with head and neck patients reporting 
greater disease-specific concerns and lowered Physical and Functional Well-Being, and 
lung patients reporting lowered Social/Family and Emotional Well-Being. Of head and 
neck patients who completed the PRO-CTCAE at baseline and at end of treatment 
(N=10), issues with taste (P-0.008) and decreased appetite were significantly more severe 
at end of treatment. Of lung patients who completed the PRO-CTCAE at baseline and 
end of treatment (N=9), there was a trend towards worsened nausea at end of treatment 
(P=0.083). The overall lack of statistically significant changes in quality of life and 
disease-specific symptoms immediately before and after treatment may be due to small 
sample sizes, or alternatively to effective management of treatment side effects.  
 
Strengths and Limitations 
This study provides valuable preliminary data on radiation treatment toxicities in 
this less well-studied, vulnerable population through use of validated ePROMs before and 
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after treatment. It adds information specifically pertaining to a diverse and underserved 
population to the existing oncology PRO literature, which predominantly characterizes 
the quality of life, treatment toxicities, and adverse events of predominantly White and 
educated patients. 17,22,24,31,34–38,48 Using EQ-5D-3L, FACT, and PRO-CTCAE allowed 
for the characterization of both overall health-related quality of life and disease-specific 
symptoms, setting the stage for improving standard of care practices and enhancing 
patient-provider discussions in the safety-net hospital setting. As additional patient data is 
added and more mature analyses can be performed with larger sample sizes, our findings 
should be useful to those seeking to understand the effects of radiation treatment on 
patient-reported health status in an underserved population. The data from this study can 
serve to facilitate prospective studies on symptoms, toxicity, and quality of life outcomes 
for cancer patients actively receiving treatment as well as cancer survivors. The limitation 
in PRO analysis at this juncture are small sample sizes, due to overall questionnaire 
participation rate as well as the time it takes to collect QOL data over a months-long 




 As patient compliance increases and more patients are seen in post-treatment 
follow-up, trends in treatment toxicities, adverse events, and quality of life during and 
after treatment will be better evaluated. ePROs obtained weekly at on-treatment visits can 
be studied in the future to examine week to week changes of symptoms and treatment 
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toxicities. During active radiotherapy treatment, acute patient-reported adverse symptoms 
were collected with site-specific PRO-CTCAE at weekly “on-treatment visits.” With 
more patient data, future studies can observe the relationship between week to week 
symptom trends and radiation treatment with or without concurrent chemotherapy. As 
patients are followed after treatment every 3 months initially and then every 6-12 months, 
prevalence and severity of short-term and long-term adverse PROs after radiotherapy can 
be assessed. Post-baseline PROs collected through disease-specific FACT questionnaires 
at 6 months and 12 months post-treatment were shown to predict clinical outcomes, such 
as death and early disease progression in a clinical trial setting with predominantly White 
patients. 20 As multiple treatment options may be available for a given cancer with 
equivalent survival outcomes but varying toxicities, population-specific symptoms and 
quality of life information obtained using PROs can help patients and providers in 
selection of the optimal therapy, galvanizing a more personalized approach to medicine. 
More data on PROs in underserved populations are urgently needed to ensure differences 
in unique socioeconomic factors are considered and incorporated into personalized 
decision making.  
Baseline PROs have also been shown to have prognostic effects for patients in 
clinical trials 21but have yet to be observed in underserved populations. A prospective 
study of the association between baseline PROs and clinical outcomes could determine if 
baseline PROs provide prognostic information for underserved populations as well. In 
doing so, physicians would be able to consider the clinical significance of their patients’ 
self-reported perspectives and thus better inform diagnostic and treatment decisions early 
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in the course of cancer care. Identifying PROs that are prognostic for cancer outcomes, 
such as survival, in this population will inform future interventions to prevent or mitigate 
adverse outcomes based on PROs data.  
Adverse PROs may be underreported through standard clinician-reported 
assessments (CROs) 15–17 and the magnitude of these disparities have not been 
characterized before in underserved populations. To observe the concordance between 
CROs and PROs, a randomized controlled study of ePROM administration could 
determine whether adverse outcomes are underreported by standard clinician reported 
assessments. PROMs capture patient symptoms and concerns that may not be readily 
captured in routine interactions with clinicians through a traditional review of systems. 
This has not been demonstrated in a vulnerable cancer patient population and will allow 
for future efforts in improving concordance rates between CROs and PROs in this 
population through culturally sensitive approaches.  
 
Assessment of Social Determinants of Health and Social Needs 
This study found that 81.8% of the eligible patients were screened for at least one 
SDH domain at Boston Medical Center using the THRIVE screening tool. This report is 
different from the study conducted across primary care clinics at BMC,40 as the study 
reports predominantly on the social needs of the patients they screened using the entire 
THRIVE screening tool. This study found that only nineteen (19.1%) study patients had 
all THRIVE SDH statuses documented whereas the remaining 61 patients received and 
answered only the Housing domain of the screener, suggesting that over the vast majority 
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of BMC patients have not been fully screened. While social needs screening and resource 
referral have been reportedly successfully implemented in 6 primary care clinics at 
BMC,40 this study demonstrates that only the Housing domain of the screening tool is 
administered to most patients, through encounters in the Emergency Department and 
inpatient admissions. In essence, our data show that screening ought to be expanded to 
more settings across the hospital.  
Of the 19 total patients who had full documentation of all 8 SDH domains of 
THRIVE, over a third of patients did so for the first time through the Radiation Oncology 
Department, affirming the need for continued administration of THRIVE in this 
department to better capture the social needs of this vulnerable patient population. When 
only observing study patients after THRIVE implementation in the Radiation Oncology 
Department, the department was able to increase total rate of SDH screening by almost 
15%. Additionally, it was able to screen over 40% of patients who had never received 
and completed the THRIVE survey before, suggesting its feasibility in this busy 
oncology department.  
The mean age of study patients with THRIVE data in EHR was 65, compared to 
40 amongst primary care patients at BMC. Married individuals and female patients were 
associated with completion of at least one THRIVE domain. Age, race, language, and 
insurance status were not associated with availability of THRIVE data. Transportation to 
medical appointments (21.1%), food insecurity (20%), and inability affording 
medications (10.5%) were the most prevalent concerns among these oncology patients, 
compared to employment (12%) food insecurity (11%), and inability affording 
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medications (11%) in the study performed across BMC Primary Care.40  These 
differences in self-reported needs for oncology patients may be a reflection of the specific 
concerns of cancer patients undergoing daily radiation treatment and experiencing 
symptoms and treatment-specific adverse events, such as weight loss and cachexia. Of 
instances in which patients demonstrated a social need, resources were requested by 
52.9%, compared to 22% of screened patients requesting resources across BMC Primary 
Care. This difference may be associated with an increased willingness to ask for help and 
knowledge of the intensity of cancer treatment.  
 
Strengths and Limitations 
This study provides valuable information on the social determinants of health 
needs of a vulnerable cancer patient population and the role of an oncology clinic in SDH 
screening. THRIVE was useful in characterizing the social needs of oncology patients 
seeking care at a safety-net hospital setting. This has improved the department’s ability to 
help patients access care and is one step forward in helping vulnerable patients access the 
cancer care continuum. These findings and methods should be useful to others who are 
seeking to implement social needs screening in a vulnerable cancer patient population in 
order to mitigate cancer health disparities.  
Overall, this study showed that electronic administration of THRIVE is possible 
amongst an oncology population. There are limitations to this study, which affect the 
generalizability of the findings. The screening was only made available to eligible head 
and neck or lung cancer patients. To better describe the SDH needs of this vulnerable 
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cancer patient population, eligibility criteria should be expanded. Sample sizes will be 




As more patients are screened for social needs, the department can begin to 
implement a systematic method to direct patients with reported needs to available 
community resources through THRIVE’s resource referral model. The implementation 
and feasibility of the referral model have been documented in BMC’s Primary Care 
Clinics. If successful, the Radiation Oncology Department could begin adding ICD-10 
codes to patient demonstrated needs such as transportation to medical appointments, food 
insecurity, and inability affording medications during appointments. As described, patient 
self-reported data encourages improved patient-provider communication.13,29  Not only 
will vulnerable cancer patients arriving to the department be able to better communicate 
social needs to providers, but the department will also be able to help address these needs 
in an efficient manner. Continued partnership with the department’s Patient Navigation 
and Social Work services will ensure patients requiring further assistance will receive the 
assistance they need. Patient access to transportation, access to food, and ability to pay 
for medication should be prioritized when improving existing services. As for any 
population, cancer care for the vulnerable goes beyond treatment. Efforts should be 
applied to reducing risk factors which lead to cancer or its recurrence. The addition of the 
THRIVE resource referral model will continue to position this department and other 
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safety-net oncology departments in a role to effectively reduce cancer health disparities 
beginning at prevention.   
 
Conclusion 
PROs have been shown to be more accurate than traditional clinician-reported 
outcomes and can even serve as prognostic markers for oncology patients. Routine PRO 
collection has been established in clinical trials and select cancer centers. Additionally, 
SDH influence a patient’s ability to access cancer care, their experience of cancer care in 
its continuum, and cancer outcomes. This study establishes that the routine administration 
of ePROMs and social needs screening is feasible yet challenging in a high-volume 
safety-net oncology clinic. This study offers preliminary PROs data, such as quality of 
life and treatment side-effects, in a less-studied underserved patient population. The study 
establishes the role of a safety-net oncology clinic in systematically and routinely 
characterizing the social needs of their patients to help vulnerable cancer patients access 
available community resources and reduce SDH burden. The successes in collecting 
PROs in a safety-net hospital setting can be used by similar settings, cancer centers, and 
even extrapolated to non-oncology settings. Overall, these findings support continued 
routine electronic questionnaire administration, with the goal of using PROs to drive 
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Appendix 2A: FACT-H&N 
 


















Appendix 2B: FACT-L 
 
 














Appendix 3A: PRO-CTCAE Lung 
	
NCI PRO-CTCAE ™ ITEMS 
Item Library Version 1.0 
English 
Form Created on 27 July 2020 
As individuals go through treatment for their cancer they sometimes experience different 
symptoms and side effects. For each question, please select the one response that best describes 
your experiences over the past 7 days… 
1a.  In the last 7 days, what was the SEVERITY of your DIFFICULTY SWALLOWING at its 
WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
 
2a.  In the last 7 days, what was the SEVERITY of your DECREASED APPETITE at its 
WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
2b.  In the last 7 days, how much did DECREASED APPETITE INTERFERE with your usual 
or daily activities? 
Ο Not at all ΟA little bit Ο Somewhat Ο Quite a bit Ο Very much 
 
3a.  In the last 7 days, how OFTEN did you have NAUSEA? 
Ο Never Ο Rarely Ο Occasionally Ο Frequently Ο Almost 
constantly 
3b.  In the last 7 days, what was the SEVERITY of your NAUSEA at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
 
4a.  In the last 7 days, how OFTEN did you have VOMITING? 
Ο Never Ο Rarely Ο Occasionally Ο Frequently Ο Almost 
constantly 
4b.  In the last 7 days, what was the SEVERITY of your VOMITING at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
 
5a.  In the last 7 days, what was the SEVERITY of your CONSTIPATION at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
 
6a.  In the last 7 days, how OFTEN did you have LOOSE OR WATERY STOOLS 
(DIARRHEA/DIARRHOEA)? 
Ο Never Ο Rarely Ο Occasionally Ο Frequently Ο Almost 
constantly 
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7a.  In the last 7 days, what was the SEVERITY of your SHORTNESS OF BREATH at its 
WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
7b.  In the last 7 days, how much did your SHORTNESS OF BREATH INTERFERE with 
your usual or daily activities? 
Ο Not at all Ο A little bit Ο Somewhat Ο Quite a bit Ο Very much 
 
8a.  In the last 7 days, what was the SEVERITY of your COUGH at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
8b.  In the last 7 days, how much did COUGH INTERFERE with your usual or daily 
activities? 
Ο Not at all Ο A little bit Ο Somewhat Ο Quite a bit Ο Very much 
 
9a.  In the last 7 days, what was the SEVERITY of your WHEEZING (WHISTLING NOISE 
IN THE CHEST WITH BREATHING) at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
 
10a.  In the last 7 days, what was the SEVERITY of your SKIN BURNS FROM RADIATION 
at their WORST? 





11a.  In the last 7 days, what was the SEVERITY of your NUMBNESS OR TINGLING IN 
YOUR HANDS OR FEET at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
11b.  In the last 7 days, how much did NUMBNESS OR TINGLING IN YOUR HANDS OR 
FEET INTERFERE with your usual or daily activities? 
Ο Not at all Ο A little bit Ο Somewhat Ο Quite a bit Ο Very much 
 
12a.  In the last 7 days, what was the SEVERITY of your DIZZINESS at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
12b.  In the last 7 days, how much did DIZZINESS INTERFERE with your usual or daily 
activities? 
Ο Not at all Ο A little bit Ο Somewhat Ο Quite a bit Ο Very much 
 
13a.  In the last 7 days, how OFTEN did you have PAIN? 
Ο Never Ο Rarely Ο Occasionally Ο Frequently Ο Almost 
constantly 
13b.  In the last 7 days, what was the SEVERITY of your PAIN at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
13c.  In the last 7 days, how much did PAIN INTERFERE with your usual or daily activities? 




14a.  In the last 7 days, what was the SEVERITY of your FATIGUE, TIREDNESS, OR 
LACK OF ENERGY at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
14b.  In the last 7 days, how much did FATIGUE, TIREDNESS, OR LACK OF ENERGY 
INTERFERE with your usual or daily activities? 
Ο Not at all Ο A little bit Ο Somewhat Ο Quite a bit Ο Very much 
 
15a.  In the last 7 days, how OFTEN did you have SHIVERING OR SHAKING CHILLS? 
Ο Never Ο Rarely Ο Occasionally Ο Frequently Ο Almost 
constantly 
15b.  In the last 7 days, what was the SEVERITY of your SHIVERING OR SHAKING 
CHILLS at their WORST? 





Do you have any other symptoms that you wish to report? 
Ο Yes Ο No 
Please list any other symptoms: 
1. In the last 7 days, what was the SEVERITY of this symptom at its 
WORST? 
O None O Mild OModerate O Severe O Very 
Severe 
2. In the last 7 days, what was the SEVERITY of this symptom at its 
WORST? 
O None O Mild OModerate O Severe O Very 
Severe 
3. In the last 7 days, what was the SEVERITY of this symptom at its 
WORST? 
O None O Mild OModerate O Severe O Very 
Severe 
4. In the last 7 days, what was the SEVERITY of this symptom at its 
WORST? 
O None O Mild OModerate O Severe O Very 
Severe 
5. In the last 7 days, what was the SEVERITY of this symptom at its 
WORST? 


















Appendix 3B: PRO-CTCAE Head and Neck 
 
NCI PRO-CTCAE ™ ITEMS 
Item Library Version 1.0 
English 
Form Created on 27 July 2020 
As individuals go through treatment for their cancer they sometimes experience different 
symptoms and side effects. For each question, please select the one response that best describes 
your experiences over the past 7 days… 
1a.  In the last 7 days, what was the SEVERITY of your DRY MOUTH at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
 
2a.  In the last 7 days, what was the SEVERITY of your DIFFICULTY SWALLOWING at its 
WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
 
3a.  In the last 7 days, what was the SEVERITY of your MOUTH OR THROAT SORES at 
their WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
3b.  In the last 7 days, how much did MOUTH OR THROAT SORES INTERFERE with your 
usual or daily activities? 
Ο Not at all Ο A little bit Ο Somewhat Ο Quite a bit Ο Very much 
 
4a.  In the last 7 days, did you have any VOICE CHANGES? 
Ο Yes Ο No 
 
5a.  In the last 7 days, what was the SEVERITY of your HOARSE VOICE at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
 
6a.  In the last 7 days, what was the SEVERITY of your PROBLEMS WITH TASTING 
FOOD OR DRINK at their WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
 
7a.  In the last 7 days, what was the SEVERITY of your DECREASED APPETITE at its 
WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
7b.  In the last 7 days, how much did DECREASED APPETITE INTERFERE with your usual 
or daily activities? 
Ο Not at all ΟA little bit Ο Somewhat Ο Quite a bit Ο Very much 
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8a.  In the last 7 days, how OFTEN did you have NAUSEA? 
Ο Never Ο Rarely Ο Occasionally Ο Frequently Ο Almost 
constantly 
8b.  In the last 7 days, what was the SEVERITY of your NAUSEA at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
 
9a.  In the last 7 days, how OFTEN did you have VOMITING? 
Ο Never Ο Rarely Ο Occasionally Ο Frequently Ο Almost 
constantly 
9b.  In the last 7 days, what was the SEVERITY of your VOMITING at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
 
10a.  In the last 7 days, how OFTEN did you have HEARTBURN? 
Ο Never Ο Rarely Ο Occasionally Ο Frequently Ο Almost 
constantly 
10b.  In the last 7 days, what was the SEVERITY of your HEARTBURN at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
 
11a.  In the last 7 days, did you have any RASH? 
Ο Yes Ο No 
 
12a.  In the last 7 days, what was the SEVERITY of your DRY SKIN at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
 
13a.  In the last 7 days, what was the SEVERITY of your ACNE OR PIMPLES ON THE 
FACE OR CHEST at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
 
14a.  In the last 7 days, did you have any HAIR LOSS? 
Ο Not at all Ο A little bit Ο Somewhat Ο Quite a bit Ο Very much 
 
15a.  In the last 7 days, what was the SEVERITY of your SKIN BURNS FROM RADIATION 
at their WORST? 





16a.  In the last 7 days, did you have any UNUSUAL DARKENING OF THE SKIN? 




17a.  In the last 7 days, what was the SEVERITY of your BLURRY VISION at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
17b.  In the last 7 days, how much did BLURRY VISION INTERFERE with your usual or 
daily activities? 
Ο Not at all Ο A little bit Ο Somewhat Ο Quite a bit Ο Very much 
 
18a.  In the last 7 days, how OFTEN did you have PAIN? 
Ο Never Ο Rarely Ο Occasionally Ο Frequently Ο Almost 
constantly 
18b.  In the last 7 days, what was the SEVERITY of your PAIN at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
18c.  In the last 7 days, how much did PAIN INTERFERE with your usual or daily activities? 
Ο Not at all Ο A little bit Ο Somewhat Ο Quite a bit Ο Very much 
 
19a.  In the last 7 days, what was the SEVERITY of your FATIGUE, TIREDNESS, OR 
LACK OF ENERGY at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
19b.  In the last 7 days, how much did FATIGUE, TIREDNESS, OR LACK OF ENERGY 
INTERFERE with your usual or daily activities? 
Ο Not at all Ο A little bit Ο Somewhat Ο Quite a bit Ο Very much 
 
20a.  In the last 7 days, how OFTEN did you feel ANXIETY? 
Ο Never Ο Rarely Ο Occasionally Ο Frequently Ο Almost 
constantly 
20b.  In the last 7 days, what was the SEVERITY of your ANXIETY at its WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
20c.  In the last 7 days, how much did ANXIETY INTERFERE with your usual or daily 
activities? 
Ο Not at all Ο A little bit Ο Somewhat Ο Quite a bit Ο Very much 
 
21a.  In the last 7 days, how OFTEN did you FEEL THAT NOTHING COULD CHEER YOU 
UP? 
Ο Never Ο Rarely Ο Occasionally Ο Frequently Ο Almost 
constantly 
21b.  In the last 7 days, what was the SEVERITY of your FEELINGS THAT NOTHING 
COULD CHEER YOU UP at their WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
21c.  In the last 7 days, how much did FEELING THAT NOTHING COULD CHEER YOU 
UP INTERFERE with your usual or daily activities? 




22a.  In the last 7 days, how OFTEN did you have SAD OR UNHAPPY FEELINGS? 
Ο Never Ο Rarely Ο Occasionally Ο Frequently Ο Almost 
constantly 
22b.  In the last 7 days, what was the SEVERITY of your SAD OR UNHAPPY FEELINGS at 
their WORST? 
Ο None Ο Mild Ο Moderate Ο Severe Ο Very severe 
22c.  In the last 7 days, how much did SAD OR UNHAPPY FEELINGS INTERFERE with 
your usual or daily activities? 
Ο Not at all Ο A little bit Ο Somewhat Ο Quite a bit Ο Very much 
 
OTHER SYMPTOMS 
Do you have any other symptoms that you wish to report? 
Ο Yes Ο No 
Please list any other symptoms: 
1. In the last 7 days, what was the SEVERITY of this symptom at its 
WORST? 
O None O Mild OModerate O Severe O Very 
Severe 
2. In the last 7 days, what was the SEVERITY of this symptom at its 
WORST? 
O None O Mild OModerate O Severe O Very 
Severe 
3. In the last 7 days, what was the SEVERITY of this symptom at its 
WORST? 
O None O Mild OModerate O Severe O Very 
Severe 
4. In the last 7 days, what was the SEVERITY of this symptom at its 
WORST? 
O None O Mild OModerate O Severe O Very 
Severe 
5. In the last 7 days, what was the SEVERITY of this symptom at its 
WORST? 
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